We are highly focused in the area of Urology. Our main product Propiverine (trademarks Mictonorm®, Mictonorm Uno®, Mictonetten®, Detrunorm®, Detrunorm® XL and BUP-4®) is used for the treatment of urinary incontinence and overactice bladder in adults and children.
We offer pharmaceuticals in highest quality as well as a wide range of services to the doctors and patients. Furthermore our urologic product range comprises modern preparations for the treatment of urinary stone diseases, urinary tract infections, benign prostate syndrom and bladder cancer.
APOGEPHA has given a great impetus to research and development and is investing nearly 15 to 20 percent of its turnover in R&D. Because of our continuous product development efforts we have launched a once-a-day formulation of Propiverine recently and this has a great impact on our revenues.
APOGEPHA has its own
- research and development team
- production site for solid oral presentations and small scale (study medications for clinical trials) for own products and for contract manufacturing
- quality control and assurance
- medical department for clinical research and medical support
- regulatory affairs departement for national, decentralized, mutual recognition and central procedures
- core competence in marketing & sales with its own sales forces for urologists and selected gynecologists, pediatricians, general practitioners and pharmacists.
On this pages you find information about overactive bladder, urinary incontinence and our international activities.